keyword
MENU ▼
Read by QxMD icon Read
search

Stage I seminoma

keyword
https://www.readbyqxmd.com/read/27915468/clinical-characteristics-of-testicular-germ-cell-tumors-in-patients-aged-50-years-and-older-a-large-scale-study-from-the-cancer-registration-committee-of-the-japanese-urological-association
#1
Taketo Kawai, Yoshinori Tanaka
OBJECTIVES: To determine the characteristics of testicular germ cell tumors in older patients. METHODS: A testicular cancer survey was carried out by the Japanese Urological Association in 2011 to register the testicular cancers diagnosed in 2005 and 2008. The survey included age, presenting symptoms, physical examination findings, tumor markers, histopathology, clinical stage, treatment and clinical outcomes. These factors were compared between patients aged ≥50 years and those aged <50 years at diagnosis...
December 4, 2016: International Journal of Urology: Official Journal of the Japanese Urological Association
https://www.readbyqxmd.com/read/27893934/surveillance-versus-adjuvant-radiotherapy-for-patients-with-high-risk-stage-i-seminoma
#2
Mette S Mortensen, Mikkel Bandak, Maria Gg Kier, Jakob Lauritsen, Mads Agerbaek, Niels V Holm, Hans von der Maase, Gedske Daugaard
BACKGROUND: The optimal treatment strategy for patients with clinical stage I (CS-1) seminoma is controversial. The objective of the current study was to evaluate the outcomes for patients considered to be at high risk of disease recurrence with a tumor size ≥6 cm. Patients were treated with either adjuvant radiotherapy (RT) or followed with surveillance. METHODS: From the Danish Testicular Cancer database, the authors identified 473 patients with CS-1 seminoma with a tumor size ≥6 cm...
November 28, 2016: Cancer
https://www.readbyqxmd.com/read/27893332/outcome-of-men-with-relapse-after-adjuvant-carboplatin-for-clinical-stage-i-seminoma
#3
Stefanie Fischer, Torgrim Tandstad, Matthew Wheater, Emilio Porfiri, Aude Fléchon, Jorge Aparicio, Dirk Klingbiel, Breda Skrbinc, Umberto Basso, Jonathan Shamash, Anja Lorch, Klaus-Peter Dieckmann, Gabriella Cohn-Cedermark, Olof Ståhl, Caroline Chau, Edurne Arriola, Kalena Marti, Paul Hutton, Brigitte Laguerre, Pablo Maroto, Jörg Beyer, Silke Gillessen
Purpose Adjuvant carboplatin is one of three management strategies that may follow inguinal orchiectomy in clinical stage I seminoma. However, little is known about the outcome of patients who experience a relapse after such treatment. Patients and Methods Data from 185 patients who relapsed after adjuvant carboplatin between January 1987 and August 2013 at 31 centers/groups from 20 countries were collected and retrospectively analyzed. Primary outcomes were disease-free survival and overall survival. Secondary outcomes were time to, stage at, and treatment of relapse as well as rate of subsequent relapses...
November 28, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/27861143/intratumoral-heterogeneity-and-chemoresistance-in-nonseminomatous-germ-cell-tumor-of-the-testis
#4
Mehmet Asim Bilen, Kenneth R Hess, Matthew T Campbell, Jennifer Wang, Russell R Broaddus, Jose A Karam, John F Ward, Christopher G Wood, Seungtaek L Choi, Priya Rao, Miao Zhang, Aung Naing, Rosale General, Diana H Cauley, Sue-Hwa Lin, Christopher J Logothetis, Louis L Pisters, Shi-Ming Tu
BACKGROUND: Nonseminomatous germ cell tumor of the testis (NSGCT) is largely curable. However, a small group of patients develop refractory disease. We investigated the hypothesis that intratumoral heterogeneity contributes to the emergence of chemoresistance and the development of refractory tumor subtypes. RESULTS: Our institution's records for January 2000 through December 2010 included 275 patients whose primary tumor showed pure embryonal carcinoma (pure E); mixed embryonal carcinoma, yolk sac tumor, and teratoma (EYT); or mixed embryonal carcinoma, yolk sac tumor, seminoma, and teratoma (EYST)...
November 16, 2016: Oncotarget
https://www.readbyqxmd.com/read/27846929/-ccafu-french-national-guidelines-2016-2018-on-testicular-germ-cell-tumors
#5
X Durand, A Fléchon, T Murez, L Rocher, P Camparo, N Morel-Journel, P-H Savoie, L Ferretti, P Sèbe, A Méjean
INTRODUCTION: The purpose of the oncologic comitee of the french association of urology was to establish guidelines proposed by the external genital organ group, for the diagnosis, treatment and follow-up of the germ cell tumours of the testis. MATERIAL AND METHODS: The multidisciplinary working group studied 2013 guidelines, exhaustively reviewed the literature, and evaluated references and their level of proof in order to attribute grades of recommandation. RESULTS: The initial workup of testicular cancer is based on clinical, laboratory (AFP, total hCG, LDH) and imaging assessment (scrotal ultrasound and chest, abdomen and pelvis computed tomography)...
November 2016: Progrès en Urologie
https://www.readbyqxmd.com/read/27816603/bilateral-testicular-germ-cell-tumors-in-the-era-of-multimodal-therapy
#6
Ryan P Kopp, Michael Chevinsky, Melanie Bernstein, George Bosl, Robert Motzer, Dean Bajorin, Darren Feldman, Brett S Carver, Joel Sheinfeld
OBJECTIVES: To characterize the incidence, presentation, management, and relapse of a large population of bilateral testicular germ cell tumors (TGCT) from a single institution. METHODS: We identified bilateral TGCT diagnosed between 1/1989 and 2/2014. We categorized synchronous and metachronous TGCT, noting time between 1(st) and 2(nd) TGCT, histology [seminoma vs. nonseminoma (NSGCT)], stage and treatments. Kaplan Meier survival estimates characterized relapse...
November 2, 2016: Urology
https://www.readbyqxmd.com/read/27791233/use-of-auc7-adjuvant-carboplatin-in-patients-with-stage-i-seminoma-systematic-review-of-the-literature
#7
Salvatore Siracusano, Alberto Diminutto, Antonio Benito Porcaro, Maria Angela Cerruto, Walter Artibani
PURPOSE: Among the adjuvant options to be proposed to patients with stage I seminoma after orchiectomy, the administration of a single cycle of carboplatin, at the dosage reaching an area under the curve of 7 mg/mL/min (AUC7), is a relatively recent introduction in clinical practice. METHODS: On April 1, 2016, we performed a systematic review of the literature to identify studies on the use of AUC7 carboplatin in the adjuvant setting for stage I seminoma patients...
October 22, 2016: Tumori
https://www.readbyqxmd.com/read/27713862/pure-stage-i-seminoma-with-an-elevated-hcg-of-25-265%C3%A2-miu-ml-a-case-report
#8
Hiromichi Katayama, Hiroshi Aoki, Katsuyuki Taguchi, Yuu Sakurada, Tomonori Sato, Masahiro Takahashi, Rie Shibuya, Hiroshi Naganuma, Shigeto Ishidoya
We report a histologically pure stage 1 seminoma with an elevated human chorionic gonadotropin (hCG). A 38 year-old man was referred for the evaluation of the left testicular swelling. He showed an elevated serum hCG level of 25,265 mIU/ml with normal a fetoprotein and lactate dehydrogenase. Imaging showed heterogeneous tumor without any metastatic lesions. We conducted 4 courses of chemotherapy before detecting hCG nadir. The final pathological report showed pure seminoma with syncytiotrophoblastic cells but no choriocarcinoma components...
November 2016: Urology Case Reports
https://www.readbyqxmd.com/read/27713801/the-association-between-institution-at-orchiectomy-and-outcomes-on-active-surveillance-for-clinical-stage-i-germ-cell-tumours
#9
Madhur Nayan, Michael A S Jewett, Lynn Anson-Cartwright, Philippe L Bedard, Malcolm Moore, Peter Chung, Padraig Warde, Joan Sweet, Martin O'Malley, Robert J Hamilton
INTRODUCTION: Institutional experience has been associated with improved outcomes for various malignancies, including testicular cancer. The present study evaluated whether institution at orchiectomy was associated with outcomes on active surveillance (AS) for clinical stage (CS) I germ cell tumours (GCT). METHODS: 815 patients with CSI GCT managed with AS at the Princess Margaret Cancer Centre were identified. Princess Margaret is a tertiary academic institution with a multidisciplinary testicular cancer clinic involving radiation oncologists, medical oncologists, and urologists, and has research experience in testicular cancer care...
May 2016: Canadian Urological Association Journal, Journal de L'Association des Urologues du Canada
https://www.readbyqxmd.com/read/27648280/long-term-outcomes-following-post-operative-radiotherapy-for-stage-i-ii-testicular-seminoma-an-australasian-single-institution-experience
#10
Wee Loon Ong, Lester Nazareth, Benjamin Hindson, Bronwyn Matheson, Jeremy L Millar
INTRODUCTION: The aim of the study is to review the long-term oncological outcomes and adverse effects of post-operative radiotherapy (PORT) for Stage I/II seminoma patients in an Australian radiation treatment centre. METHODS: This is a retrospective study of 125 patients with Stage I/II seminoma treated with PORT at the Alfred Health Radiation Oncology Service between 1992 and 2013. Patients were linked to the Victorian Cancer Registry to enable confirmation of survival and diagnosis of secondary malignancies (SM)...
September 2016: Journal of Medical Radiation Sciences
https://www.readbyqxmd.com/read/27618772/management-of-stage-i-testicular-germ-cell-tumours
#11
Michal Chovanec, Nasser Hanna, K Clint Cary, Lawrence Einhorn, Costantine Albany
Clinical stage I testicular germ cell tumours (TGCT) are highly curable neoplasms. The treatment of stage I testicular cancer is complex and requires a multidisciplinary approach. Standard options after radical orchiectomy for seminoma include active surveillance, radiation therapy or 1-2 cycles of carboplatin, and options for nonseminoma include active surveillance, retroperitoneal lymph node dissection (RPLND) or 1-2 cycles of bleomycin plus etoposide plus cisplatin (BEP). All the options should be discussed with each patient and treatment choices should be made by shared decision making as virtually all patients with clinical stage I TGCT can be cured of their disease...
September 13, 2016: Nature Reviews. Urology
https://www.readbyqxmd.com/read/27556300/adjuvant-radiation-therapy-in-stage-i-seminoma-20-years-of-oncologic-results
#12
Francesca De Felice, Daniela Musio, Giovanni Luca Gravina, Francesco Marampon, Vincenzo Tombolini
AIM: To report long term oncologic outcomes after adjuvant radiotherapy (RT) for stage I seminoma. METHOD: We reviewed the complete data set for all patients treated at our institute between 1988 and 2005 for stage I seminoma with adjuvant RT after radical orchiectomy . RESULTS: A total of 85 patients were included. The median follow-up was 15 years. The 20-year overall survival (OS) and relapse free survival (RFS) were 92% and 96.3%, respectively...
August 18, 2016: Oncotarget
https://www.readbyqxmd.com/read/27527805/conditional-risk-of-relapse-in-surveillance-for-clinical-stage-i-testicular-cancer
#13
Madhur Nayan, Michael A S Jewett, Ali Hosni, Lynn Anson-Cartwright, Philippe L Bedard, Malcolm Moore, Aaron R Hansen, Peter Chung, Padraig Warde, Joan Sweet, Martin O'Malley, Eshetu G Atenafu, Robert J Hamilton
BACKGROUND: Patients on surveillance for clinical stage I (CSI) testicular cancer are counseled regarding their baseline risk of relapse. The conditional risk of relapse (cRR), which provides prognostic information on patients who have survived for a period of time without relapse, have not been determined for CSI testicular cancer. OBJECTIVE: To determine cRR in CSI testicular cancer. DESIGN, SETTING, AND PARTICIPANTS: We reviewed 1239 patients with CSI testicular cancer managed with surveillance at a tertiary academic centre between 1980 and 2014...
August 12, 2016: European Urology
https://www.readbyqxmd.com/read/27527410/the-evolving-management-of-patients-with-clinical-stage-i-seminoma
#14
Richard S Matulewicz, Daniel T Oberlin, Joel Sheinfeld, Joshua J Meeks
OBJECTIVE: To determine trends in management and factors associated with men receiving either chemotherapy or radiation therapy post orchiectomy for clinical stage I (CSI) seminoma in a contemporary setting. PATIENTS AND METHODS: The National Cancer Data Base was queried for all patients with CSI seminoma from 1998 to 2012. Adjuvant treatment after orchiectomy was classified into 3 groups: surveillance, radiotherapy, and chemotherapy. Yearly trends in management are described...
August 12, 2016: Urology
https://www.readbyqxmd.com/read/27487789/fibrillin-1-fbn-1-a-new-marker-of-germ-cell-neoplasia-in-situ
#15
Z Cierna, M Mego, I Jurisica, K Machalekova, M Chovanec, V Miskovska, D Svetlovska, K Kalavska, K Rejlekova, K Kajo, J Mardiak, P Babal
BACKGROUND: Germ cell neoplasia in situ (GCNIS), is preinvasive stage of testicular germ cell tumours (TGCTs). Fibrillins, which are integral components of microfibrils are suggested to be involved in cancer pathogenesis and maintenance of embryonic stem cells pluripotency. The aim of this study was to examine fibrillin-1 (FBN-1) expression in TGCTs patients. METHODS: Surgical specimens from 203 patients with TGCTs were included into the translational study. FBN-1 expression was evaluated in the tumour tissue, in GCNIS and in adjacent non-neoplastic testicular tissue in all available cases...
2016: BMC Cancer
https://www.readbyqxmd.com/read/27339401/clinical-characteristics-and-outcomes-of-late-relapse-in-stage-i-testicular-seminoma
#16
A Hosni, P Warde, M Jewett, P Bedard, R Hamilton, M Moore, M Nayan, R Huang, E G Atenafu, M O'Malley, J Sweet, P Chung
AIMS: To identify the characteristics and outcomes associated with late relapse in stage I seminoma. MATERIALS AND METHODS: A retrospective review was carried out of all patients with stage I seminoma managed at our institution between 1981 and 2011. Data were obtained from a prospectively maintained database. Late relapse was defined as tumour recurrence > 2 years after orchiectomy. RESULTS: Overall, 1060 stage I seminoma patients were managed with active surveillance (n=766) or adjuvant radiotherapy (n=294)...
October 2016: Clinical Oncology: a Journal of the Royal College of Radiologists
https://www.readbyqxmd.com/read/27123324/best-treatment-option-for-clinical-stage-i-seminoma-patients
#17
Emre Tüzel
No abstract text is available yet for this article.
2016: Central European Journal of Urology
https://www.readbyqxmd.com/read/27123323/controversies-in-the-management-of-clinical-stage-i-testicular-seminoma
#18
Martina Ondrusova, Sona Balogova, Viera Lehotska, Karol Kajo, Bela Mrinakova, Dalibor Ondrus
INTRODUCTION: Following orchiectomy patients with clinical stage I (CSI) testicular seminoma may be managed by active surveillance (AS) or adjuvant treatment (radiotherapy or chemotherapy). In view of the published data on long-term toxicity, mainly second malignant neoplasms (SMNs), adjuvant radiotherapy (ART) is currently no longer recommended as adjuvant therapy for these patients. The purpose of our recent study was to compare the impact of two selected treatment approaches - AS versus adjuvant chemotherapy (ACT) on survival in patients with CSI testicular seminoma...
2016: Central European Journal of Urology
https://www.readbyqxmd.com/read/27052649/treatment-of-stage-i-seminoma-with-one-course-of-adjuvant-carboplatin-or-surveillance-risk-adapted-recommendations-implementing-patient-autonomy-a-report-from-the-swedish-and-norwegian-testicular-cancer-group-swenoteca
#19
T Tandstad, O Ståhl, O Dahl, H S Haugnes, U Håkansson, Å Karlsdottir, A Kjellman, C W Langberg, A Laurell, J Oldenburg, A Solberg, K Söderström, U Stierner, E Cavallin-Ståhl, R Wahlqvist, N Wall, G Cohn-Cedermark
BACKGROUND: The purpose of the protocol was to reduce the treatment burden in clinical stage I (CSI) seminoma by offering risk-adapted treatment. The protocol aimed to prospectively validate the proposed risk factors for relapse, stromal invasion of the rete testis and tumor diameter >4 cm, and to evaluate the efficacy of one course of adjuvant carboplatin. PATIENTS AND METHODS: From 2007 to 2010, 897 patients were included in a prospective, population-based, risk-adapted treatment protocol implementing one course of adjuvant carboplatin AUC7 (n = 469) or surveillance (n = 422)...
July 2016: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/26996661/late-relapses-in-stage-i-testicular-cancer-patients-on-surveillance
#20
Mette Saksø Mortensen, Jakob Lauritsen, Maria Gry Gundgaard Kier, Mikkel Bandak, Ane Lindegaard Appelt, Mads Agerbæk, Niels Vilstrup Holm, Mette Moe Kempel, Hans von der Maase, Gedske Daugaard
BACKGROUND: Comprehensive data on late relapse (LR) and very LR (VLR) in patients with clinical stage I (CS-1) testicular cancer followed on surveillance are missing. These data are essential for planning optimal follow-up. OBJECTIVE: Assess incidence and outcome of LR (>2 yr) and VLR (>5 yr) in a large cohort of CS-1 surveillance patients, and examine differences in the clinical characteristics of patients with early relapse (ER), LR, and VLR. DESIGN, SETTING, AND PARTICIPANTS: CS-1 surveillance patients diagnosed between 1984 and 2007 were identified from the retrospective Danish Testicular Cancer (DaTeCa) database...
August 2016: European Urology
keyword
keyword
110966
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"